Parkinson disease

60,305views

test

00:00 / 00:00

Parkinson disease

Watch later

Watch later

Coronary artery disease: Clinical
Inflammatory bowel disease: Pathology review
Crohn disease
Ulcerative colitis
Inflammatory bowel disease: Clinical
Macrocytic anemia: Pathology review
Anemia: Clinical
Extrinsic hemolytic normocytic anemia: Pathology review
Microcytic anemia: Pathology review
Sideroblastic anemia
Autoimmune hemolytic anemia
Iron deficiency anemia
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Anemia of chronic disease
Folate (Vitamin B9) deficiency
Pancreatitis: Pathology review
Pancreatitis: Clinical
Acute pancreatitis
Chronic pancreatitis
Superior mesenteric artery syndrome
Diverticulosis and diverticulitis
Diverticular disease: Pathology review
Diverticular disease: Clinical
Appendicitis: Clinical
Appendicitis
Appendicitis: Pathology review
Irritable bowel syndrome
Anatomy of the abdominal viscera: Large intestine
Vitamin B12 deficiency
Myocardial infarction
ECG cardiac infarction and ischemia
Clot retraction and fibrinolysis
Platelet plug formation (primary hemostasis)
Erythropoietin
Coagulation (secondary hemostasis)
Atrial fibrillation
Anticoagulants: Warfarin
Heart failure
Heart failure: Pathology review
Heart failure: Clinical
Ventricular fibrillation
Ventricular tachycardia
Class III antiarrhythmics: Potassium channel blockers
Atrial flutter
Ventricular arrhythmias: Pathology review
Supraventricular arrhythmias: Pathology review
Acute kidney injury: Clinical
Kidney stones: Pathology review
Kidney stones
Glomerular filtration
Long QT syndrome and Torsade de pointes
Hyperkalemia
Hyperkalemia: Clinical
Chronic kidney disease
Chronic kidney disease: Clinical
Hyperphosphatemia
Hypercalcemia
Kidney stones: Clinical
Renal failure: Pathology review
Diabetes mellitus: Clinical
Metabolic acidosis
Class I antiarrhythmics: Sodium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Class II antiarrhythmics: Beta blockers
Positive inotropic medications
Hyponatremia: Clinical
Hyponatremia
Hypernatremia: Clinical
Hypernatremia
Chronic obstructive pulmonary disease (COPD): Clinical
Obstructive lung diseases: Pathology review
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Emphysema
Pulmonary hypertension
Cor pulmonale
Chronic bronchitis
Muscarinic antagonists
Asthma: Clinical
Asthma
Pulmonary embolism
Deep vein thrombosis and pulmonary embolism: Pathology review
Venous thromboembolism: Clinical
Pneumonia: Pathology review
Pneumonia
Pneumonia: Clinical
Ventilation-perfusion ratios and V/Q mismatch
Shock: Clinical
Shock: Pathology review
Shock
Factor V Leiden
Anticoagulants: Heparin
Hyperthyroidism medications
Hyperthyroidism: Pathology review
Hyperthyroidism: Clinical
Hypothyroidism and thyroiditis: Clinical
Hypothyroidism: Pathology review
Hypothyroidism medications
Pheochromocytoma
Adrenal masses: Pathology review
Renal artery stenosis
Hyperaldosteronism
Respiratory distress syndrome: Pathology review
Acute respiratory distress syndrome: Clinical
Diabetes insipidus and SIADH: Pathology review
Pericardial disease: Clinical
Dementia and delirium: Clinical
Lewy body dementia
Alzheimer disease
Parkinson disease
Anti-parkinson medications
Traumatic brain injury: Clinical
Concussion and traumatic brain injury
Brown-Sequard Syndrome
Cauda equina syndrome
Meningitis
Myasthenia gravis
Multiple sclerosis
Stroke: Clinical
Cerebral vascular disease: Pathology review
Alcohol use disorder
Seizures: Clinical

Assessments

Flashcards

0 / 21 complete

USMLE® Step 1 questions

0 / 6 complete

High Yield Notes

10 pages

Flashcards

Parkinson disease

0 of 21 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 6 complete

A 70-year-old man with a history of Parkinson disease comes to the office for follow-up. He was diagnosed 6 years ago, and since then, the condition has been well-controlled with levodopa/carbidopa. However, for the past 2 months, the patient reports increased difficulty ambulating, loss of balance and increased rigidity. He is compliant with the treatment and describes fluctuations in the symptoms that improve after he takes the medication. Physical examination reveals diffuse cogwheel rigidity and difficulty walking. A decision is made to add a medication that will descrease the symptoms between levodopa/carbidopa doses. Which of the following best describes the mechanism of action of this medication?  

External References

First Aid

2024

2023

2022

2021

Akinesia in Parkinson disease p. 725

Antimuscarinic drugs

Parkinson disease p. 563

Antipsychotic drugs p. 591

Parkinson-like syndrome p. 250

Dopamine p. 241, 332

Parkinson disease p. 563

Gait disturbance

Parkinson disease p. 537

Gait disturbances

Parkinson disease p. 725

MAO inhibitors p. 593

Parkinson disease p. 563

Metoclopramide p. 407

Parkinson-like syndrome p. 250

Muscarinic antagonists p. 240, 706

Parkinson disease p. 563

Nausea

Parkinson disease drugs p. 564

Neurons p. 502

Parkinson disease p. 563

Parkinson disease p. 534

basal ganglia lesions p. 524

benztropine for p. 240

dopaminergic pathways p. 509

drug therapy for p. 563

Lewy bodies p. 534

neurotransmitters for p. 507

nigrostriatal pathway and p. 509

presentation p. 725

proteasome and p. 46

resting tremor in p. 533

seborrheic dermatitis association p. 484

trihexyphenidyl p. 240

Parkinson-like syndrome p. 250

Reserpine

Parkinson-like syndrome p. 250

Rigidity in Parkinson disease p. 725

Substantia nigra

Parkinson disease p. 725

Transcript

Watch video only

Parkinson’s disease, which is sometimes called Parkinson disease, Parkinson’s, or PD, is a movement disorder where the dopamine-producing neurons in the substantia nigra of the brain undergo degeneration.

Parkinson’s is one of the most common neurological disorders. It’s a progressive, adult-onset disease, and it gets more common with age. Most of the time, there’s no known cause. But in a few cases, there might be a genetic cause, like mutations in the PINK1, parkin, or alpha synuclein genes, and in rare cases, Parkinsonian symptoms may be caused by MPTP, a toxic impurity that can be found in the recreational drug MPPP or desmethylprodine, which is a synthetic opioid.

In other people, one or more risk factors, rather than a single outright cause, might contribute to Parkinson’s, for example pesticide exposure or DNA variants in genes like LRRK2.

No matter what the cause is, Parkinson’s derives from the death of dopamine-producing, or dopaminergic, neurons in the substantia nigra. The name substantia nigra means “black substance,” since it is darker than other brain regions when you look at a slice of the brain on an autopsy.

We usually refer to the substantia nigra as if it’s in a single location, but there are actually two of these regions in the brain, one on each side of the midbrain. The substantia nigra is a part of the basal ganglia, a collection of brain regions that control movement through their connections with the motor cortex.

In Parkinson’s, these darkened areas of substantia nigra gradually disappear. Under a microscope, Lewy bodies, which are eosinophilic, round inclusions made of alpha-synuclein protein are present in the affected substantia nigra neurons before they die. The function of alpha-synuclein is unknown, as well as the significance of Lewy bodies, and they are both found in other diseases like Lewy body dementia and multiple system atrophy.

The substantia nigra actually can be split into two sub-regions.

First, there’s the pars reticulata, which receives signals from another part of the basal ganglia called the striatum, which is a term for the caudate and putamen put together, and relays messages to the thalamus via neurons rich in the neurotransmitter GABA, also known as gamma-aminobutyric acid.

Second, there’s the pars compacta, and this is the part of the substantia nigra affected in Parkinson’s. The pars compacta sends messages to the striatum via neurons rich in the neurotransmitter dopamine, forming the nigrostriatal pathway, which helps to stimulate the cerebral cortex and initiate movement. Therefore, when substantia nigra pars compacta neurons die, the individual may be in a hypokinetic or low movement state which is commonly seen in Parkinson’s.

In addition to simply initiating movements, the substantia nigra helps to calibrate and fine tune the way that movements happen, which leads to the clinical features of Parkinson’s.

First there’s tremor, which is an involuntary shakiness most noticeable in the hands—characteristically called a “pill-rolling” tremor because it looks like someone rolling a pill between their thumb and index finger. This is a “resting tremor,” meaning it is present at rest and diminishes with intentional movement.

Next there’s rigidity, which refers to stiffness that can appear as “cogwheel” rigidity, which is when there are a series of catches or stalls as a person’s arms or legs are passively moved by someone else. Rigidity is also responsible for the stooped posture and an almost expressionless face that some individuals with Parkinson’s might have.

Summary

Parkinson's is a progressive movement disorder caused by degeneration of dopamine-producing neurons in the substantia nigra, specifically in the pars compacta, which leads to resting tremor, rigidity, problems initiating movement, and postural instability, and for which therapy primarily focuses on increasing brain dopamine.

There is no cure for this condition, but medications can increase dopamine levels in the brain and control tremors. There is also deep-brain stimulation, which involves an implantable device that directly sends electrical signals to the basal ganglia that counteract the abnormal signaling in Parkinson's.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 7/E (ENHANCED EBOOK)" McGraw Hill Professional (2014)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw Hill Professional (2019)
  5. "Parkinson's disease" The Lancet (2015)
  6. "Parkinson's disease" The Lancet (2004)